Fox Chase Cancer Center News

Philadelphia (October 30, 2011) – In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

Chevy Chase, MD (October 27, 2011) – A recent study to be published in The Endocrine Society’s December 2011 print issue of the Journal of Clinical Endocrinology & Metabolism (JCEM) found that a behavioral intervention to lower dietary intake of total fat and saturated fat that also encouraged increased consumption of foods that are good sources of dietary fiber during late childhood and adolescence resulted in significantly lower fasting plasma glucose levels and lower systolic blood pressure when study participants were re-evaluated in young adulthood.

PHILADELPHIA (October 17, 2011) – The Pennsylvania Breast Cancer Coalition (PBCC) is pleased to work with the Philadelphia County Exhibit Committee and Fox Chase Cancer Center to bring its traveling photo exhibit67 Women, 67 Counties: Facing Breast Cancer in Pennsylvania, to Philadelphia County from October 20th through October 30th. The photo exhibit, sponsored in part by Fox Chase’s Office of Health Communications and Health Disparities, will be displayed in the Women’s Cancer Center at Fox Chase located at 333 Cottman Avenue in Philadelphia. An opening reception is

PHILADELPHIA (October 17, 2011) – Come join Skyler Kleger, 7th grade student

Philadelphia (October 10, 2011) – Two internationally recognized scientists with strong Philadelphia ties are to receive the 2011 John Scott Award.

MIAMI BEACH, FL (October 5, 2011)––Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, and estimate prognosis: the Prostate Specific Antigen Level (PSA), Gleason score (GS) from the biopsy, and the digital rectal exam findings (DRE).

MIAMI BEACH, FL (October 5, 2011) — Prostate cancer is the most common cancer in men in the United States, as well as the second leading cause of cancer-related deaths in this population. Many of these patients undergo surgical removal of their prostate, followed by radiation therapy applied to their prostate bed — the space where the prostate was once situated.

MIAMI BEACH, FL (October 4, 2011)––After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, is the first detectable sign of the cancer's return to the prostate. Fox Chase Cancer Center researchers have found that the time between the last radiation treatment and biochemical failure can accurately predict a patient's risk of death of prostate cancer.